The Europe Osteoporosis Drugs Market would witness market growth of 4% CAGR during the forecast period (2020-2026). Growth in the market for osteoporosis drugs is likely to be delayed due to side effects and risks involved with osteoporosis medications. For eg, heartburn, muscle and joint pain, diarrhea, and stomach or esophagus ulcers are risks associated with the drug class of bisphosphonates. Other than this, other classes of drugs also have side effects in patients. Many risks caused by osteoporosis medications include bone trauma, bone breaks, and urinary infection. Moreover, the patent expiry of new branded products and the restricted reimbursement by healthcare payers often adversely affect the growth of the market.
Rank ligand inhibitors may also be used in conjunction with other drugs to give a synergistic effect on the overall treatment regimen. It is also anticipated that this factor will be one of the key factors responsible for presenting lucrative opportunities. Other advantages related to ligand rank Inhibitors such as decreased bone cell turnover and increased bone mineral density, resulting in high demand.
The major factor contributing to the growth of the market for osteoporosis drugs is the increase in the prevalence of osteoporosis. In addition, other reasons that fuel the growth of the osteoporosis drugs market are the rise for the geriatric population worldwide and the rise in sedentary lifestyles worldwide. However, the adverse effects of osteoporosis medications and the time-consuming medication development procedure impede the expansion of the demand for osteoporosis medicines. Conversely, strong growth potential in developed economies is projected to generate attractive prospects over the forecast period.
Based on Route of Administration, the market is segmented into Oral, Injectable and Other Route of Administration. Based on Drug Class, the market is segmented into Bisphosphonates, Rank Ligand Inhibitors, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Other Drug Classes. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: Osteoporosis Drugs Market in Europe is expected to register a CAGR of 4% during the forecast period (2020-2026)
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC (GSK), Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., Allergan PLC, and Eli Lilly and Company
Scope of the Europe Osteoporosis Drugs Market Analysis
Market Segmentation:
By Route of Administration
- Oral
- Injectable and
- Other Route of Administration
By Drug Class
- Bisphosphonates
- Rank Ligand Inhibitors
- Parathyroid Hormone Therapy
- Calcitonin
- Selective Estrogen Inhibitors Modulator (SERM) and
- Other Drug Classes
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Companies Profiled
- Amgen, Inc.
- Hoffmann-La Roche Ltd.
- GlaxoSmithKline PLC (GSK)
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Allergan PLC
- Eli Lilly and Company
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Osteoporosis Drugs Market, by Route of Administration
1.4.2 Europe Osteoporosis Drugs Market, by Drug Class
1.4.3 Europe Osteoporosis Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Osteoporosis Drugs Market by Route of Administration
3.1 Europe Oral Market by Country
3.2 Europe Injectable Market by Country
3.3 Europe Other Route of Administration Market by Country
Chapter 4. Europe Osteoporosis Drugs Market by Drug Class
4.1 Europe Bisphosphonates Market by Country
4.2 Europe Rank Ligand Inhibitors Market by Country
4.3 Europe Parathyroid Hormone Therapy Market by Country
4.4 Europe Calcitonin Market by Country
4.5 Europe Other Drug Class Market by Country
Chapter 5. Europe Osteoporosis Drugs Market by Country
5.1 Germany Osteoporosis Drugs Market
5.1.1 Germany Osteoporosis Drugs Market by Route of Administration
5.1.2 Germany Osteoporosis Drugs Market by Drug Class
5.2 UK Osteoporosis Drugs Market
5.2.1 UK Osteoporosis Drugs Market by Route of Administration
5.2.2 UK Osteoporosis Drugs Market by Drug Class
5.3 France Osteoporosis Drugs Market
5.3.1 France Osteoporosis Drugs Market by Route of Administration
5.3.2 France Osteoporosis Drugs Market by Drug Class
5.4 Russia Osteoporosis Drugs Market
5.4.1 Russia Osteoporosis Drugs Market by Route of Administration
5.4.2 Russia Osteoporosis Drugs Market by Drug Class
5.5 Spain Osteoporosis Drugs Market
5.5.1 Spain Osteoporosis Drugs Market by Route of Administration
5.5.2 Spain Osteoporosis Drugs Market by Drug Class
5.6 Italy Osteoporosis Drugs Market
5.6.1 Italy Osteoporosis Drugs Market by Route of Administration
5.6.2 Italy Osteoporosis Drugs Market by Drug Class
5.7 Rest of Europe Osteoporosis Drugs Market
5.7.1 Rest of Europe Osteoporosis Drugs Market by Route of Administration
5.7.2 Rest of Europe Osteoporosis Drugs Market by Drug Class
Chapter 6. Company Profiles
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Research & Development Expense
6.1.4 Recent strategies and developments:
6.1.4.1 Partnerships, Collaborations, and Agreements:
6.1.4.2 Approvals:
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.3 GlaxoSmithKline PLC (GSK)
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.4 Merck & Co., Inc.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expenses
6.5 Novartis AG
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Recent strategies and developments:
6.5.4.1 Partnerships, Collaborations, and Agreements:
6.6 Pfizer, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 Sun Pharmaceutical Industries Ltd.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.8 Teva Pharmaceutical Industries Ltd.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expenses
6.9 Allergan PLC
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense
6.1 Eli Lilly and Company
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Regional Analysis
6.10.4 Research & Development Expense
TABLE 1 Europe Osteoporosis Drugs Market, 2016 - 2019, USD Million
TABLE 2 Europe Osteoporosis Drugs Market, 2020 - 2026, USD Million
TABLE 3 Europe Osteoporosis Drugs Market by Route of Administration, 2016 - 2019, USD Million
TABLE 4 Europe Osteoporosis Drugs Market by Route of Administration, 2020 - 2026, USD Million
TABLE 5 Europe Oral Market by Country, 2016 - 2019, USD Million
TABLE 6 Europe Oral Market by Country, 2020 - 2026, USD Million
TABLE 7 Europe Injectable Market by Country, 2016 - 2019, USD Million
TABLE 8 Europe Injectable Market by Country, 2020 - 2026, USD Million
TABLE 9 Europe Other Route of Administration Market by Country, 2016 - 2019, USD Million
TABLE 10 Europe Other Route of Administration Market by Country, 2020 - 2026, USD Million
TABLE 11 Europe Osteoporosis Drugs Market by Drug Class, 2016 - 2019, USD Million
TABLE 12 Europe Osteoporosis Drugs Market by Drug Class, 2020 - 2026, USD Million
TABLE 13 Europe Bisphosphonates Market by Country, 2016 - 2019, USD Million
TABLE 14 Europe Bisphosphonates Market by Country, 2020 - 2026, USD Million
TABLE 15 Europe Rank Ligand Inhibitors Market by Country, 2016 - 2019, USD Million
TABLE 16 Europe Rank Ligand Inhibitors Market by Country, 2020 - 2026, USD Million
TABLE 17 Europe Parathyroid Hormone Therapy Market by Country, 2016 - 2019, USD Million
TABLE 18 Europe Parathyroid Hormone Therapy Market by Country, 2020 - 2026, USD Million
TABLE 19 Europe Calcitonin Market by Country, 2016 - 2019, USD Million
TABLE 20 Europe Calcitonin Market by Country, 2020 - 2026, USD Million
TABLE 21 Europe Other Drug Class Market by Country, 2016 - 2019, USD Million
TABLE 22 Europe Other Drug Class Market by Country, 2020 - 2026, USD Million
TABLE 23 Europe Osteoporosis Drugs Market by Country, 2016 - 2019, USD Million
TABLE 24 Europe Osteoporosis Drugs Market by Country, 2020 - 2026, USD Million
TABLE 25 Germany Osteoporosis Drugs Market, 2016 - 2019, USD Million
TABLE 26 Germany Osteoporosis Drugs Market, 2020 - 2026, USD Million
TABLE 27 Germany Osteoporosis Drugs Market by Route of Administration, 2016 - 2019, USD Million
TABLE 28 Germany Osteoporosis Drugs Market by Route of Administration, 2020 - 2026, USD Million
TABLE 29 Germany Osteoporosis Drugs Market by Drug Class, 2016 - 2019, USD Million
TABLE 30 Germany Osteoporosis Drugs Market by Drug Class, 2020 - 2026, USD Million
TABLE 31 UK Osteoporosis Drugs Market, 2016 - 2019, USD Million
TABLE 32 UK Osteoporosis Drugs Market, 2020 - 2026, USD Million
TABLE 33 UK Osteoporosis Drugs Market by Route of Administration, 2016 - 2019, USD Million
TABLE 34 UK Osteoporosis Drugs Market by Route of Administration, 2020 - 2026, USD Million
TABLE 35 UK Osteoporosis Drugs Market by Drug Class, 2016 - 2019, USD Million
TABLE 36 UK Osteoporosis Drugs Market by Drug Class, 2020 - 2026, USD Million
TABLE 37 France Osteoporosis Drugs Market, 2016 - 2019, USD Million
TABLE 38 France Osteoporosis Drugs Market, 2020 - 2026, USD Million
TABLE 39 France Osteoporosis Drugs Market by Route of Administration, 2016 - 2019, USD Million
TABLE 40 France Osteoporosis Drugs Market by Route of Administration, 2020 - 2026, USD Million
TABLE 41 France Osteoporosis Drugs Market by Drug Class, 2016 - 2019, USD Million
TABLE 42 France Osteoporosis Drugs Market by Drug Class, 2020 - 2026, USD Million
TABLE 43 Russia Osteoporosis Drugs Market, 2016 - 2019, USD Million
TABLE 44 Russia Osteoporosis Drugs Market, 2020 - 2026, USD Million
TABLE 45 Russia Osteoporosis Drugs Market by Route of Administration, 2016 - 2019, USD Million
TABLE 46 Russia Osteoporosis Drugs Market by Route of Administration, 2020 - 2026, USD Million
TABLE 47 Russia Osteoporosis Drugs Market by Drug Class, 2016 - 2019, USD Million
TABLE 48 Russia Osteoporosis Drugs Market by Drug Class, 2020 - 2026, USD Million
TABLE 49 Spain Osteoporosis Drugs Market, 2016 - 2019, USD Million
TABLE 50 Spain Osteoporosis Drugs Market, 2020 - 2026, USD Million
TABLE 51 Spain Osteoporosis Drugs Market by Route of Administration, 2016 - 2019, USD Million
TABLE 52 Spain Osteoporosis Drugs Market by Route of Administration, 2020 - 2026, USD Million
TABLE 53 Spain Osteoporosis Drugs Market by Drug Class, 2016 - 2019, USD Million
TABLE 54 Spain Osteoporosis Drugs Market by Drug Class, 2020 - 2026, USD Million
TABLE 55 Italy Osteoporosis Drugs Market, 2016 - 2019, USD Million
TABLE 56 Italy Osteoporosis Drugs Market, 2020 - 2026, USD Million
TABLE 57 Italy Osteoporosis Drugs Market by Route of Administration, 2016 - 2019, USD Million
TABLE 58 Italy Osteoporosis Drugs Market by Route of Administration, 2020 - 2026, USD Million
TABLE 59 Italy Osteoporosis Drugs Market by Drug Class, 2016 - 2019, USD Million
TABLE 60 Italy Osteoporosis Drugs Market by Drug Class, 2020 - 2026, USD Million
TABLE 61 Rest of Europe Osteoporosis Drugs Market, 2016 - 2019, USD Million
TABLE 62 Rest of Europe Osteoporosis Drugs Market, 2020 - 2026, USD Million
TABLE 63 Rest of Europe Osteoporosis Drugs Market by Route of Administration, 2016 - 2019, USD Million
TABLE 64 Rest of Europe Osteoporosis Drugs Market by Route of Administration, 2020 - 2026, USD Million
TABLE 65 Rest of Europe Osteoporosis Drugs Market by Drug Class, 2016 - 2019, USD Million
TABLE 66 Rest of Europe Osteoporosis Drugs Market by Drug Class, 2020 - 2026, USD Million
TABLE 67 Key Information – Amgen, Inc.
TABLE 68 key information – F. Hoffmann-La Roche Ltd.
TABLE 69 Key Information – GlaxoSmithKline PLC (GSK)
TABLE 70 key information - Merck & Co., Inc.
TABLE 71 Key Information – Novartis AG
TABLE 72 Key Information – Pfizer, Inc.
TABLE 73 Key Information – Sun Pharmaceutical Industries Ltd.
TABLE 74 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 75 Key Information – Allergan PLC
TABLE 76 Key Information – Eli Lilly and Company
List of Figures
FIG 1 Methodology for the research